Assisted suicideDrug approvalPsychedelic drugsTerminal care
Key points
Argues that UK drug regulation is inconsistent, favoring assisted-suicide drugs over psychedelics despite differing evidence bases.
Abstract
This editorial highlights the UK's drug regulatory double standards. Drugs for assisted suicide would bypass standard regulation despite limited evidence, while psychedelics face significant barriers despite promising evidence internationally. I argue that drugs for assisted suicide should meet the same regulatory standards, and psychedelics should be rescheduled to enable further clinical research.